Biotech company Can-Fite announced development of its drug candidate CF102, which is currently in phase 2 trials for liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis.
Can-Fite BioPharma announced that it has entered into definitive agreements with existing institutional investors in regard to a secondary offering.
Can-Fite Biopharma announced that its oncology drug candidate has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
Source: ThinkstockOver the past week, a few biotech companies made absolutely massive runs and some had serious falls. In the past year, the health care sector was on fire from positive trials, U.S....
Can-Fite BioPharma is building momentum with its most recent designation from the FDA.